AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Summary

Samsung Medical Centre, Seoul, Korea. Additional 0\~5 Korea Lung Cancer Consortium (KLCC) centres in Korea Up to 40 subjects will be enrolled in two-stages (first stage: 19 evaluable subjects and second stage: 17 evaluable subjects and additional 4 subjects considering the drop out rate) If the study is conducted as de-escalated dosage (Durvalumab 1120mg) after the safety run-in, number of the patients will be counted from the second safety-run in phase.

Timeline

Start

2020-09-18

Primary completion

2022-01-14

Completion

2022-01-14

Outcome

Outcome not reported

Stopped: “Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with the same drug.”

Drugs

Indications